Our deals: China partnership between Octimet Oncology and Shanghai Allist Pharmaceuticals

Octimet Oncology announces licensing deal with Shanghai Allist Pharmaceuticals for Greater China

OCTIMET Oncology NV, a clinical-stage Belgian life science company with a focus on the development of highly selective, differentiated MET kinase inhibitor, announced the licensing of Greater China rights for its lead clinical compound OMO-1 and a second preclinical asset exclusively to Shanghai Allist Pharmaceuticals Co., Ltd.

OMO-1 is an oral, highly selective small molecule MET kinase inhibitor, that has demonstrated potent single agent and combination activity in a range of preclinical cancer models. OMO-1 has been evaluated in a monotherapy setting as well as in combination with small molecule EGFR tyrosine kinase inhibitors (TKIs) in Europe, showing a favorable safety profile and early signs of efficacy in MET-selected cancer patients. MET amplification is known to be a key driver of resistance to EGFR TKIs.

Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist’s third generation EGFR TKI Furmonertinib (AST2818).

In China, more than 38% of NSCLC patients harbor activating EGFR mutations, making the region ideal for completing expanded clinical efficacy studies more rapidly whilst addressing a large potential market.

For more information read the full press release.

More on subject(s)   Follow us at LinkedIn

Stay up to date